What the Research Actually Says (and How to Tell Them Apart) If you've shopped the Semax family, you've probably noticed three names that get used almost interchangeably, Semax, N-Acetyl Semax Amidate (NASA), and Adamax, plus a lot of vendors who can't agree on what's in the vial. They are not the same molecule, and the difference shows up cleanly on a Certificate of Analysis. Here's the research picture on each, then a quick-reference cheat sheet for reading your COA. Semax Semax is the parent compound: a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) built from the ACTH(4-7) fragment with a Pro-Gly-Pro tail bolted on to resist enzymatic breakdown. It was registered as a drug in Russia back in 1994 for ischemic stroke and cognitive impairment, which is why it has the deepest evidence base of the three. What the research consistently shows: - BDNF and NGF upregulation. The most consistently documented molecular mechanism of Semax is upregulation of BDNF and NGF in hippocampal and cortical tissue, the growth factors that underpin synaptic plasticity, learning, and memory consolidation. - Monoamine modulation. Semax increases dopamine turnover in the striatum and prefrontal cortex and modulates serotonin metabolites across multiple brain regions, which lines up with its activating, focus-oriented profile in rodent models. - Neuroprotection. In cerebral ischemia models it reduces infarct volume and upregulates anti-apoptotic Bcl-2 family members. - No corticosteroid activity. Unlike its parent molecule ACTH, Semax has no corticosteroid-stimulating activity, you get the neurotrophic effects without the adrenal/cortisol axis being pulled in. One honest caveat for the community: Western evidence is largely preclinical, and most human data comes from Russian-language clinical publications. N-Acetyl Semax Amidate (NASA) Same seven-amino-acid backbone, with two terminal modifications: an acetyl group on the N-terminus and amidation on the C-terminus. Those caps are the whole point, they shield the peptide from the aminopeptidases and carboxypeptidases that chew on the unprotected ends of regular Semax.

If you have friends who won't stop asking you about peptides...send them here. You can actually get paid for it.. Anyone who joins through your referral link earns you a commission. Once they're in, just go to your Skool settings and request the payout. Simple as that. Be smart about where you share your invite link though. Don't post it on other Skool groups or anywhere it'll read as spam. Stick to people who are already asking. Those are the easiest conversations anyway. To find your link on mobile: Tap the 3 dots in the top right → Invite → copy your link. Anyone who signs up through it is automatically tracked as your referral.

Has anyone tried Selank and Semax versus N-Acetyl Selank Amidate and N-Acetyl Semax Amidate? Curious as to what you thought was better..

I've seen alot of posts lately about injectable SLU-PP-332...specifically the DMSO-based solutions floating around. I want to address this directly because I think it's important for anyone in this community doing serious research. The short answer: injectable SLU-PP-332 in DMSO is a bad idea, and here's why. The Formulation Problem SLU-PP-332 is a moderately lipophilic small molecule (MW ~290 Da). DMSO can dissolve it in the vial just fine — but the moment you inject it, it hits aqueous interstitial fluid and the whole game changes. You get rapid dilution, potential supersaturation, and microcrystal formation. Those crystals can lodge in capillaries and tissue, causing sterile inflammation, granulomas, or worse if someone is foolish enough to go IV. This isn't theoretical. Lipophilic compounds without proper solubilizing excipients, think cyclodextrins, surfactants, lipid nanoparticles, PEG/Tween blends, routinely precipitate post-injection. The published preclinical work (Billon et al., 2023/2024) used carefully controlled pharmaceutical-grade vehicles for IP injection in rodents. Nobody is doing that with gray-market DMSO solutions. There's No Validated Injectable Protocol Zero published literature exists on IM, SC, or IV formulations in humans. That means: - Unknown safe injection volume and site - Unknown local tissue tolerance (pain, necrosis risk) - Unknown systemic PK when first-pass metabolism is bypassed - No human safety data - none The published rodent studies used intraperitoneal injection with pharmaceutical vehicles. That's a long way from someone pinning a DMSO solution subcutaneously. Bypassing First-Pass May Actually Be a Problem SLU-PP-332 likely undergoes CYP450 hepatic metabolism — the specific pathways aren't fully characterized yet, but that first-pass filtering is probably doing something useful. Bypass it with injection and you're potentially spiking parent drug concentrations into territory with zero dose-response data to guide you.

New Article on X about Unlocking Longevity at the Cellular Level https://x.com/startmyresearch/status/2062350509680267394